ATE315935T1 - Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten - Google Patents

Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten

Info

Publication number
ATE315935T1
ATE315935T1 AT03720879T AT03720879T ATE315935T1 AT E315935 T1 ATE315935 T1 AT E315935T1 AT 03720879 T AT03720879 T AT 03720879T AT 03720879 T AT03720879 T AT 03720879T AT E315935 T1 ATE315935 T1 AT E315935T1
Authority
AT
Austria
Prior art keywords
ethylphenyl
subject
triazole
methoxyphenyl
treatment
Prior art date
Application number
AT03720879T
Other languages
English (en)
Inventor
L Battistini
G Borsellino
Santis R De
P Carminati
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE315935T1 publication Critical patent/ATE315935T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03720879T 2002-05-03 2003-04-15 Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten ATE315935T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/137,699 US6797722B2 (en) 2002-05-03 2002-05-03 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ATE315935T1 true ATE315935T1 (de) 2006-02-15

Family

ID=29269138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03720879T ATE315935T1 (de) 2002-05-03 2003-04-15 Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten

Country Status (15)

Country Link
US (2) US6797722B2 (de)
EP (1) EP1501505B1 (de)
JP (1) JP2005529904A (de)
KR (1) KR20040111491A (de)
AT (1) ATE315935T1 (de)
AU (1) AU2003224453A1 (de)
CA (1) CA2483904A1 (de)
DE (1) DE60303296T2 (de)
DK (1) DK1501505T3 (de)
ES (1) ES2257666T3 (de)
MX (1) MXPA04010785A (de)
PL (1) PL374252A1 (de)
PT (1) PT1501505E (de)
TW (1) TWI284532B (de)
WO (1) WO2003092681A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044503A1 (es) * 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
EP1921073A1 (de) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole als Sigma Rezeptoren Hemmstoffe

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4379155A (en) * 1979-06-11 1983-04-05 Gruppo Lepetit S.P.A. 3,5-Disubstituted-1H-1,2,4-triazole derivatives
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
DE3808283A1 (de) * 1988-03-12 1989-09-21 Boehringer Ingelheim Kg Neue 3,4,5-substituierte 4h-1,2,4-triazole, ihre herstellung und verwendung
US4895872A (en) * 1989-03-15 1990-01-23 Cetus Corporation Immunosupressive analogues and derivatives of succinylacetone
US5273979A (en) * 1991-08-01 1993-12-28 Merck & Co., Inc. C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel
WO1997026278A1 (en) * 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
CN1137086C (zh) * 1997-04-04 2004-02-04 三菱制药株式会社 2-氨基丙烷-1,3-二醇化合物、其作为医药的用途及其合成中间体
IT1292092B1 (it) * 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
EP1099695A1 (de) * 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-Aryl-1H-1,2,4-triazolverbindungen als Cyclooxygenase-2 Inhibitoren und diese enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
JP2005529904A (ja) 2005-10-06
EP1501505A1 (de) 2005-02-02
KR20040111491A (ko) 2004-12-31
DE60303296T2 (de) 2006-08-17
DE60303296D1 (de) 2006-04-06
ES2257666T3 (es) 2006-08-01
PL374252A1 (en) 2005-10-03
EP1501505B1 (de) 2006-01-18
PT1501505E (pt) 2006-05-31
MXPA04010785A (es) 2005-03-07
US20050026980A1 (en) 2005-02-03
US20030207931A1 (en) 2003-11-06
DK1501505T3 (da) 2006-05-22
US6797722B2 (en) 2004-09-28
CA2483904A1 (en) 2003-11-13
TWI284532B (en) 2007-08-01
WO2003092681A1 (en) 2003-11-13
TW200418464A (en) 2004-10-01
AU2003224453A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
EA200500856A1 (ru) Новые химические соединения
BG108857A (en) Glutaminyl based dpiv inhibitors
ATE451104T1 (de) Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
ATE450268T1 (de) G-csf zur behandlung von amyotropher lateralsklerose
ATE287731T1 (de) Inhibition von histondeacetylase zur behandlung von herzhypertrophie
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DK1654287T3 (da) CD20-bindende polypeptidsammensætninger
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE502005009201D1 (de) Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
DE69936785D1 (de) Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung
DE602005016729D1 (de) Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung
ATE315935T1 (de) Verwendung von (3-(2-ethylphenyl)-5- methoxyphenyl)-1h-(1,2,4)-triazol zur behandung von autoimmunkrankheiten
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60308045D1 (de) Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes
DE60233555D1 (de) Die nukleotidsequenz ann bindende zink-finger domänen
ATE352295T1 (de) Verwendung von quinazolinen zur behandlung von t- zell vermittelten krankheiten
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
PT672124E (pt) Utilizacao de uma sequencia de dna codificadora de uma proteina que degrada acido oxalico como gene de seleccao
ATE546154T1 (de) Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen
ATE245438T1 (de) Verwendung von oligomerem matrixprotein aus knorpel zur behandlung von rheumatoider arthritis
DE69936779D1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
DE60230641D1 (de) Lentivirale vektoren zur behandlung von schmerzen
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1501505

Country of ref document: EP

REN Ceased due to non-payment of the annual fee